Artal Group S.A. I Teos Therapeutics, Inc. Transaction History

Artal Group S.A.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 12, 2022	SELL	$31.92 - $47.45 $4.6 Million - $6.84 Million	-144,047 Reduced 26.48%	400,000 $12.9 Million
Q4 2021 Feb 11, 2022	SELL	$26.23 - $47.86 $11.8 Million - $21.5 Million	-450,000 Reduced 45.27%	544,047 $25.3 Million
Q2 2021 Aug 13, 2021	SELL	$17.9 - $36.1 $1.79 Million - $3.61 Million	-100,000 Reduced 9.14%	994,047 $25.5 Million
Q3 2020 Nov 13, 2020	BUY	$17.57 - $32.92 $19.2 Million - $36 Million	1,094,047 New	1,094,047 $27 Million

149

33.3M

454K

2.45M

Ticker ITOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,575,300
Market Cap $263M
Description
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.